Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Decision Diagnostics Corp. (OTC: DECN).

Full DD Report for DECN

You must become a subscriber to view this report.


Recent News from (OTC: DECN)

DECN Releases its Strategic IP And Product Development Introduction Plan With a Summary of 2018 Achievements and 2019 Expectations
IP AND PRODUCTS STRATEGY IS PUT IN PLACE TO INCREASE REVENUES, BUILD THE BRAND AND POSITION THE COMPANY FOR A HANDSOME SETTLEMENT OR M&A TRANSACTION ++ LOS ANGELES, CA / ACCESSWIRE / December 11, 2018 / Decision Diagnostics Corp. (OTC:PINK: DECN) Decision Diagnostics Corp. is a 16 ...
Source: ACCESSWIRE
Date: December, 11 2018 06:12
DECN Receives Completed Clinical Trials Report from its IRB and Anticipates Filing its U.S. FDA 510k Application for its Genchoice! Product on December 21, 2018
DECN to Launch Genchoice! Product in Select International Markets January 2, 2019 and to File gor CE Mark in the EU and Health Canada Approval in Early 2019 LOS ANGELES, CA / ACCESSWIRE / December 4, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused b...
Source: ACCESSWIRE
Date: December, 04 2018 09:10
DECN CEO Keith M. Berman Is Interviewed By Prestigious Wall Street Reporter Who Describe Company And Products As ''Game Changer''
Wall Street Reporter Posts Interview On Its Web Site For All Interested Parties To Listen And To Learn About The Vast Potential Of Decn LOS ANGELES, CA / ACCESSWIRE / November 27, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16-year-old, diabetes-focused bio-technology R&...
Source: ACCESSWIRE
Date: November, 27 2018 09:10
DECN Receives Completed Clinical Trial Data, Charts and Spreadsheets Essential for its Imminent Genchoice! Test Strip
Company to Begin Sales in Select International Markets While the U.S. FDA Reviews its 510k Application LOS ANGELES, CA / ACCESSWIRE / November 6, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16-year-old, diabetes-focused bio-technology R&D firm, manufacturer, quality pla...
Source: ACCESSWIRE
Date: November, 06 2018 09:10
DECN Set to Appeal the Clearly Unfair Ruling in Court's Termination of the DECN Patent Infringement and False Advertising Case Battle with Johnson & Johnson
Court Decides After 10 Months to Modify the Seminal Legal Question at Issue, Thereby Handing J&J an Easy Victory They Do Not Deserve and Have Not Earned LOS ANGELES, CA / ACCESSWIRE / October 30, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused b...
Source: ACCESSWIRE
Date: October, 30 2018 09:10
DECN Board Of Directors In Final Review Of Preliminary Financing Agreement For $4.75 Million Investment
LOS ANGELES, CA / ACCESSWIRE / September 13, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales...
Source: ACCESSWIRE
Date: September, 13 2018 08:00
DECN Announces Major Step Ahead with Offering Statement
DECN Receives "No Comment" Letter from SEC, Providing Ability, Upon Formal Qualification, to Raise Up to $7.5 Million in Financing Under Regulation A LOS ANGELES, CA / ACCESSWIRE / September 6, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) (the "Company") is a 16 year old, diabetes-f...
Source: ACCESSWIRE
Date: September, 06 2018 09:20
DECN Announces Significant Updates For Products And Programs
Company Discusses Its Gensure!, Genchoice And, Genprecis Products, The Genprecis Precise Meter, And The New Petsure And, Petultimate Products And Petultimate Avantage Meter, Plus Our Big Box Hybrid Private Label Program LOS ANGELES, CA / ACCESSWIRE / August 14, 2018 / Decision Diagnosti...
Source: ACCESSWIRE
Date: August, 14 2018 09:20
DECN Makes Its Mark In $1+ Billion Dollar Pet Diabetes & Glucose Testing Market With Two New Products, Petsure! & Petultimate!
Petsure! Test Strips Currently On Sale Commercially With New Proprietary Petultimate! Test Strips And Avantage! Meter To Be In Distribution Early In 4th Quarter LOS ANGELES, CA / ACCESSWIRE / August 7, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused...
Source: ACCESSWIRE
Date: August, 07 2018 09:20
Decision Diagnostics Corp. Announces Election of Two Key Managers to the Board of Its Korean Partner ''The Bio Co, Ltd.''
DECN Also Reports Major Progress Toward the Completion of Clinical Trials Testing of Its Genchoice! Strip, Begins Final Preparations for International Product Launch LOS ANGELES, CA / ACCESSWIRE / July 12, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-foc...
Source: ACCESSWIRE
Date: July, 12 2018 09:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.0210.01970.02780.01965258,086
2018-12-100.01650.022760.02340.0161724,773
2018-12-070.020.019830.020.0166278,153
2018-12-060.0450.020.0450.0166454,248
2018-12-050.0190.0220.0250.0165232,627

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-11219,751258,08685.1464Short
2018-12-10407,200724,77356.1831Short
2018-12-077,500278,1532.6964Cover
2018-12-06175,256454,24838.5816Short
2018-12-04145,376232,62762.4932Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DECN.


About Decision Diagnostics Corp. (OTC: DECN)

Logo for Decision Diagnostics Corp. (OTC: DECN)

Decision Diagnostics Corp. is a nationwide prescription and non prescription diagnostics and home testing products distributor. We also market our Genstrip , GenUltimate and GenSure Glucose Test Strip for diabetics, the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early .

 

 

 

Current Management

  • Keith M Berman / CFO
    • Chief Financial Officer, Secretary and Director Specializing in invitro diagnostics and healthcare software including intranet and Internet systems for the past years and a founder of Decision Diagnostics Corp., Keith Berman brings more than years experience in the healthcare field, having worked with such companies as Technicon Corporation and BoehringerMannheim Corporation. He is the founder of Medicius Inc., and served as that company s president at the time of its acquisition by what is today, Decision Diagnostics Corp. Mr. Berman also was the founder of Cymedix, the operating division of the formerly Amex traded Ramp Corp. formerly Medix Resources AMEX: RCO , a public company. Mr. Berman received his B.A. and M.B.A. from Indiana University.
  • Robert Jagunich / Chairman
    • Chairman and Director Robert Jagunich brings years of experience in the medical systems and device industry. Since joining Decision Diagnostics Corp., Mr. Jagunich has also served president at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. From April through December , he served as a director of Cymedix Corporation, the operating division of Ramp Corp. AMEX: RCO . Mr. Jagunich also has provided consulting services to such clients as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. He received his B.S., M.S. and M.B.A. from the University of Michigan.

Current Share Structure

  • Market Cap: $4,544,061 - 03/09/2018
  • Authorized: 494,995,000 - 05/08/2017
  • Issue and Outstanding: 90,881,210 - 05/08/2017
  • Float: 79,519,393 - 05/08/2017

 


Recent Filings from (OTC: DECN)

Quarterly Report - OTC PINK 3Q 2017 BALANCE SHEET_FOOTNOTES_STATEMENTS OF CASH FLOWS & EQUITY REVISED
Filing Type: Quarterly Report - OTC PINK 3Q 2017 BALANCE SHEET_FOOTNOTES_STATEMENTS OF CASH FLOWS & EQUITY REFiling Source: OTC Markets
Filing Date: November, 17 2017
Supplemental Information - OTC PINK QUARTERLY REPORT 3Q 2017
Filing Type: Supplemental Information - OTC PINK QUARTERLY REPORT 3Q 2017Filing Source: OTC Markets
Filing Date: November, 14 2017
Management Discussion and Analysis - OTC PINK QUARTERLY REPORT FOR 3Q 2017
Filing Type: Management Discussion and Analysis - OTC PINK QUARTERLY REPORT FOR 3Q 2017Filing Source: OTC Markets
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: DECN)

Daily Technical Chart for (OTC: DECN)


Stay tuned for daily updates and more on (OTC: DECN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DECN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DECN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DECN and does not buy, sell, or trade any shares of DECN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/